Balcik, O. S. Et Al. 2011. Serum thrombin activatable fibrinolysis inhibitor levels in patients with newly diagnosed multiple myeloma. Blood Coagulation and Fibrinolysis , vol.22, no.4 , 260-263.

Balcik, O. S., Albayrak, M., Uyar, M. E., Dagdas, S., Yokus, O., Ceran, F., ... Cipil, H.(2011). Serum thrombin activatable fibrinolysis inhibitor levels in patients with newly diagnosed multiple myeloma. Blood Coagulation and Fibrinolysis , vol.22, no.4, 260-263.

Balcik, Ozlem Et Al. "Serum thrombin activatable fibrinolysis inhibitor levels in patients with newly diagnosed multiple myeloma," Blood Coagulation and Fibrinolysis , vol.22, no.4, 260-263, 2011

Balcik, Ozlem S. Et Al. "Serum thrombin activatable fibrinolysis inhibitor levels in patients with newly diagnosed multiple myeloma." Blood Coagulation and Fibrinolysis , vol.22, no.4, pp.260-263, 2011

Balcik, O. S. Et Al. (2011) . "Serum thrombin activatable fibrinolysis inhibitor levels in patients with newly diagnosed multiple myeloma." Blood Coagulation and Fibrinolysis , vol.22, no.4, pp.260-263.

@article{article, author={Ozlem S. Balcik Et Al. }, title={Serum thrombin activatable fibrinolysis inhibitor levels in patients with newly diagnosed multiple myeloma}, journal={Blood Coagulation and Fibrinolysis}, year=2011, pages={260-263} }